NFKB1 and Parkinson disease: In a Parkinson's disease mouse model, paquinimod treatment downregulated the expression of inflammatory cytokines (IL‐6, IL‐1β and TNF‐α) and suppressed the TLR4/NF‐κB signalling pathway [43].